Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-20

Clinical Trial Update: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 efficacy confirmation study of CDP870 in early rheumatoid arthritis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CDP870 (certolizumab pegol)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-11-20